Cancer Research and Treatment

Seok Jin Nam

18 Articles

Breast cancer

Impact of Social Support during Diagnosis and Treatment on Disease Progression in Young Patients with Breast Cancer: A Prospective Cohort Study: Danbee Kang, Seri Park, Hyo Jung Kim, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Se Kyung Lee, Ji-Yeon Kim, Seok Jin Nam, Juhee Cho, Yeon Hee Park; Cancer Res Treat. 2024;56(1):125-133. Published online September 4, 2023; DOI: https://doi.org/10.4143/crt.2023.673

Abstract PDF PubReader ePub: Purpose
We evaluated the association between changes in social support after cancer treatment and recurrence-free survival (RFS) in such patients using a prospective cohort study.
Materials and Methods
Data were obtained from a prospective cohort study (NCT03131089) conducted at Samsung Medical Center (2013-2021). The primary outcome measure was RFS. Social support was measured using the social and family well-being (SFWB) domain of the Functional Assessment of Cancer Therapy-General. We calculated the changes in SFWB scores before and during treatment and the hazard ratio for RFS by comparing such changes.
Results
The mean±standard deviation (SD) age of the patients was 35±3.9 years, and 71.5% and 64.8% of the patients were married and had children, respectively. The mean±SD SFWB score at baseline was 20.5±5.0 out of 26. After cancer treatment, 35.9%, 10.3%, and 53.8% of the participants had increasing, unchanged, and decreasing SFWB scores, respectively. The decreasing SFWB score group had a higher risk of mortality or recurrence than the increasing group. Risk factors for the decreasing score were the presence of children during diagnosis.
Conclusion
In this cohort, changes in social support after treatment were associated with RFS in young patients with breast cancer. Health professionals should develop family interventions to help them receive proper social support.

3,073 View
204 Download

General

Effectiveness of Self-Assessment, TAilored Information, and Lifestyle Management for Cancer Patients’ Returning to Work (START): A Multi-center, Randomized Controlled Trial: Danbee Kang, Ka Ryeong Bae, Yeojin Ahn, Nayeon Kim, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Young Mog Shim, Dong Hyun Sinn, Seung Yeop Oh, Mison Chun, Jaesung Heo, Juhee Cho; Cancer Res Treat. 2023;55(2):419-428. Published online November 8, 2022; DOI: https://doi.org/10.4143/crt.2022.939

Abstract PDF Supplementary Material PubReader ePub

Purpose
We developed a comprehensive return to work (RTW) intervention covering physical, psycho-social and practical issues for patients newly diagnosed and evaluated its efficacy in terms of RTW.
Materials and Methods
A multi-center randomized controlled trial was done to evaluate the efficacy of the intervention conducted at two university-based cancer centers in Korea. The intervention program comprised educational material at diagnosis, a face-to-face educational session at completion of active treatment, and three individualized telephone counseling sessions. The control group received other education at enrollment.
Results
At 1-month post-intervention (T2), the intervention group was more likely to be working compared to the control group after controlling working status at diagnosis (65.4% vs. 55.9%, p=0.037). Among patients who did not work at baseline, the intervention group was 1.99-times more likely to be working at T2. The mean of knowledge score was higher in the intervention group compared to the control group (7.4 vs. 6.8, p=0.029). At the 1-year follow-up, the intervention group was 65% (95% confidence interval, 0.78 to 3.48) more likely to have higher odds for having work.
Conclusion
The intervention improved work-related knowledge and was effective in facilitating cancer patients’ RTW.

Citations

Citations to this article as recorded by

Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
A visualized and bibliometric analysis of cancer vocational rehabilitation research using CiteSpace
Zebing Luo, Xuejia Liu, Chujun Chen
Work.2024; : 1. CrossRef
Psychosocial Adjustment Experiences Among Nasopharyngeal Carcinoma Survivors
Jie Jiang, Ming-Hui Yan, Yu-Ying Fan, Jun-E Zhang
Cancer Nursing.2023;[Epub] CrossRef

4,349 View
138 Download
2 Web of Science
3 Crossref

Breast cancer

Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience: Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park; Cancer Res Treat. 2022;54(4):1091-1098. Published online January 10, 2022; DOI: https://doi.org/10.4143/crt.2021.901

Abstract PDF Supplementary Material PubReader ePub

Purpose
Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist.
Materials and Methods
We retrospectively reviewed medical records of patients with early or locally advanced HER2-positive BC who underwent neoadjuvant TCHP followed by curative surgery at Samsung Medical Center between January 2016 and August 2020.
Results
Of 447 patients, 316 (70.7%) received breast-conserving surgery and 131 (29.3%) received total mastectomy. In terms of neoadjuvant chemotherapy response, pathologic complete response (pCR) and residual cancer burden (RCB) score were analyzed. The rate of pCR was 64% a class of RCB 0 was observed in 65% of cases, RCB class I in 12%, RCB class II in 14%, and RCB class III in 2%. The 3-year event-free survival rate was 90.6%, BC with pCR occurred in 92.8%, and BC with non-pCR in 86.3% (p=0.016). In terms of distant metastasis, the 3-year distant recurrence-free survival rate was 93.5%; BC with pCR occurred in 95.9% and BC with non-pCR in 89.2% (p=0.013). Mucositis (85.2%), pain (83.2%), and diarrhea (70.5%) were the most common non-hematologic adverse events. In terms of hematologic adverse events, anemia (89.9%) was the most commonly observed adverse events followed by thrombocytopenia (29.8%).
Conclusion
Neoadjuvant TCHP therapy had a pCR rate of 64% and a 3-year event-free survival of 90% in real world experience. In terms of toxicity profile, anemia was frequently observed and adequate management including occasional transfusion was required.

Citations

Citations to this article as recorded by

De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
Song Wu, Li Bian, Haibo Wang, Shaohua Zhang, Tao Wang, Zhigang Yu, Jianbin Li, Feng Li, Kun Wang, Zefei Jiang
World Journal of Surgical Oncology.2024;[Epub] CrossRef
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
Haizhu Chen, Xiujuan Gui, Ziwei Zhou, Fengxi Su, Chang Gong, Shunrong Li, Wei Wu, Nanyan Rao, Qiang Liu, Herui Yao
The Breast.2024; 75: 103733. CrossRef
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study
Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, Berna Oksuzoglu, Ahmet Sezer, Nuri Karadurmus, Erdem Cubukcu, Mehmet Ali Nahit Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Abdallah T. M. Shbair, Cagatay Arslan, Ahmet Taner Sumbul, Sem
Acta Oncologica.2023; 62(4): 381. CrossRef
Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials
Faizan Fazal, Muhammad Nauman Bashir, Maham Leeza Adil, Usama Tanveer, Mansoor Ahmed, Taha Zahid Chaudhry, Ali Ahmad Ijaz, Muhammad Haider
Cureus.2023;[Epub] CrossRef
Trends of axillary surgery in breast cancer patients with axillary lymph node metastasis: a comprehensive single-center retrospective study
Yeon Jin Kim, Hye Jin Kim, Soo Yeon Chung, Se Kyung Lee, Byung Joo Chae, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jai Min Ryu
Annals of Surgical Treatment and Research.2023; 105(1): 10. CrossRef
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
Inês Soares de Pinho, Paulo Luz, Lucy Alves, Raquel Lopes-Brás, Vanessa Patel, Miguel Esperança-Martins, Lisa Gonçalves, Ritas Freitas, Diana Simão, Maria Roldán Galnares, Isabel Fernandes, Silvia Artacho Criado, Salvador Gamez Casado, Jose Baena Cañada,
Clinical Drug Investigation.2023; 43(9): 691. CrossRef
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
The Breast.2023; 72: 103594. CrossRef
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer
Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, Min Hwan Kim, Jae Ho Jeong, Ji-Yeon Kim, Dae-Won Lee, Jin-Hee Ahn, Heejung Chae, Kyung-Hun Lee, Jee Hyun Kim, Keun Seok Lee, Joo Hyuk Sohn, Yoon-La Choi, Seock-Ah Im, Kyung Hae Jung, Yeon Hee Park
JAMA Oncology.2022; 8(9): 1271. CrossRef

7,725 View
583 Download
9 Web of Science
8 Crossref

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients: Yoon Ju Bang, Won Kyung Kwon, Seok Jin Nam, Seok Won Kim, Byung-Joo Chae, Se Kyung Lee, Jai Min Ryu, Jong-Won Kim, Jonghan Yu, Jeong Eon Lee; Cancer Res Treat. 2022;54(3):827-833. Published online October 13, 2021; DOI: https://doi.org/10.4143/crt.2021.791

Abstract PDF Supplementary Material PubReader ePub

Purpose
Double heterozygosity (DH) for BRCA1 and BRCA2 variant is very rare with only a few cases reported, and most those in Caucasians. In this article, we present seven unrelated cases of DH for BRCA1/2 identified from a single institution in Korea, and describe the characteristics and phenotype of DH individuals compared to those with a single BRCA variant.
Materials and Methods
This study included 27,678 patients diagnosed with breast cancer and surgically treated at Samsung Medical Center (SMC) between January 2008 and June 2020. In total, 4,215 high-risk breast cancer patients were tested for the BRCA1/2 genes, and electronic medical records from 456 cases with pathogenic/likely pathogenic variants (PVs/LPVs) were reviewed.
Results
A younger mean age at diagnosis was associated with DH than a single variant of BRCA1/2. More triple-negative breast cancer (TNBC) and higher nuclear and histologic grade cancer occurred with DH than BRCA2 variant. All 7 cases of DH were unrelated, and their mutation combinations were different. There were no Ashkenazi founder variants detected.
Conclusion
We suggest that patients with DH for BRCA1/2 variants develop breast cancer at a younger age, but the histopathologic features are similar to those of BRCA1.

Citations

Citations to this article as recorded by

Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US
Junjie Pan, Ning Ren, Lanqi Ren, YiBei Yang, Qiaoping Xu
Scientific Reports.2024;[Epub] CrossRef
Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants
Song Wen, Meng Zhang, Jiuan Chen, Li Hu, Jie Sun, Lu Yao, Ye Xu, Juan Zhang, Yuntao Xie
Breast Cancer Research and Treatment.2024; 208(1): 155. CrossRef
Discovery of BRCA1/BRCA2 founder variants by haplotype analysis
Won Kyung Kwon, Hyeok-Jae Jang, Jeong Eon Lee, Yeon Hee Park, Jai Min Ryu, Jonghan Yu, Ja-Hyun Jang, Jong-Won Kim
Cancer Genetics.2022; 266-267: 19. CrossRef

6,284 View
245 Download
3 Web of Science
3 Crossref

Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors: Sungkeun Shim, Danbee Kang, Nayeon Kim, Gayeon Han, Jihyun Lim, Hyunsoo Kim, Jeonghyun Park, Mankyung Lee, Jeong Eon Lee, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Jai Min Ryu, Seok Jin Nam, Se Kyung Lee, Juhee Cho; Cancer Res Treat. 2022;54(3):834-841. Published online October 13, 2021; DOI: https://doi.org/10.4143/crt.2021.784

Abstract PDF Supplementary Material PubReader ePub

Purpose
Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors.
Materials and Methods
We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques.
Results
The COST-K demonstrated good internal consistency, with a Cronbach’s α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=–0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, –0.18; constipation, –0.14; diarrhea, –0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean±standard deivation [SD], 27.1±7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity.
Conclusion
The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.

Citations

Citations to this article as recorded by

Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy
Jeremy P. Harris, Eric Ku, Garrett Harada, Sophie Hsu, Elaine Chiao, Pranathi Rao, Erin Healy, Misako Nagasaka, Jessica Humphreys, Michael A. Hoyt
American Journal of Hospice and Palliative Medicine®.2024; 41(6): 592. CrossRef
Financial Toxicity in Radiation Oncology: Impact for Our Patients and for Practicing Radiation Oncologists
Victoria S. Wu, Xinglei Shen, Janet de Moor, Fumiko Chino, Jonathan Klein
Advances in Radiation Oncology.2024; 9(3): 101419. CrossRef
Measures of financial toxicity in cancer survivors: a systematic review
L. B. Thomy, M. Crichton, L. Jones, P. M. Yates, N. H. Hart, L. G. Collins, R. J. Chan
Supportive Care in Cancer.2024;[Epub] CrossRef
Validation of the COmprehensive Score for Financial Toxicity (COST) in Vietnamese patients with cancer
Binh Thang Tran, Dinh Duong Le, Thanh Gia Nguyen, Minh Tu Nguyen, Minh Hanh Nguyen, Cao Khoa Dang, Dinh Trung Tran, Le An Pham
PLOS ONE.2024; 19(6): e0306339. CrossRef
Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis
Stevanus Pangestu, Fanni Rencz
Value in Health.2023; 26(2): 300. CrossRef
Association between financial toxicity and health-related quality of life of patients with gynecologic cancer
Yusuke Kajimoto, Kazunori Honda, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takashi Shibutani, Shoji Nagao, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Keiichi Fujiwara, Ataru Igarashi
International Journal of Clinical Oncology.2023; 28(3): 454. CrossRef
Financial Toxicity Following Cancer in a Middle-Income Country with a Pluralistic Health System: Validation of the COST Questionnaire
Veni V. Sakti, Mahmoud Danaee, Cheng-Har Yip, Ros S. A. Bustamam, Marniza Saad, Gin Gin Gan, Jerome Tan, Yueh Ni Lim, Flora L.T. Chong, Murallitharan Munisamy, Farahida Mohd Farid, Boon Lui Sew, Yek-Ching Kong, Nishalini Muniandy, Nirmala Bhoo-Pathy
Cancer Care Research Online.2023; 3(3): e044. CrossRef
Financial Toxicity Among Breast Cancer Patients
Yi Kuang, Xiaoyi Yuan, Zheng Zhu, Weijie Xing
Cancer Nursing.2023;[Epub] CrossRef
Heterogeneity of financial toxicity and associated risk factors for older cancer survivors in China
Mingzhu Su, Siqi Liu, Li Liu, Fang Wang, Jiahui Lao, Xiaojie Sun
iScience.2023; 26(10): 107768. CrossRef
Evaluation of financial toxicity and associated factors in female patients with breast cancer: a systematic review and meta-analysis
Yusuf Çeli̇k, Sevilay Şenol Çeli̇k, Seda Sarıköse, Hande Nur Arslan
Supportive Care in Cancer.2023;[Epub] CrossRef
Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer
Yusuke Kajimoto, Takashi Shibutani, Shoji Nagao, Satoshi Yamaguchi, Shiro Suzuki, Masahiko Mori, Hirofumi Tsubouchi, Kohshiro Nakao, Anri Azuma, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Kazunori Honda, Ataru Igarashi
International Journal of Gynecologic Cancer.2022; : ijgc-2022-003410. CrossRef

7,106 View
184 Download
9 Web of Science
11 Crossref

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer: Ji-Yeon Kim, Kyunghee Park, Hae Hyun Jung, Eunjin Lee, Eun Yoon Cho, Kwang Hee Lee, Soo Youn Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2016;48(4):1338-1350. Published online February 18, 2016; DOI: https://doi.org/10.4143/crt.2015.430

Abstract PDF Supplementary Material PubReader ePub

Purpose
TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC).
Materials and Methods
We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients.
Results
Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36± 132.73 vs. 339.61±143.21 vs. 99.53±99.57,respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patientswith a TP53 missense mutation (5-year distantrecurrence-free survival [5Y DRFS]: low vs. high, 50.0% vs. 87.8%; p=0.009), while high mRNA expression with a TP53 deletion mutation indicated poor prognosis (5Y DRFS: low vs. high, 91.7% vs. 75.0%; p=0.316).
Conclusion
Association between TP53 mutation and expression indicates a potential prognostic marker of TNBC; hence both DNA sequencing and mRNA expression analysis may be required to predict the prognosis of TNBC patients.

Citations

Citations to this article as recorded by

Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer
Rachel Han, Sharon Nofech-Mozes, Dina Boles, Hannah Wu, Nikolina Curcin, Elzbieta Slodkowska
International Journal of Surgical Pathology.2024; 32(2): 239. CrossRef
Exploring Biomarkers in Breast Cancer: Hallmarks of Diagnosis, Treatment, and Follow-Up in Clinical Practice
Laura Lopez-Gonzalez, Alicia Sanchez Cendra, Cristina Sanchez Cendra, Eduardo David Roberts Cervantes, Javier Cassinello Espinosa, Tatiana Pekarek, Oscar Fraile-Martinez, Cielo García-Montero, Ana María Rodriguez-Slocker, Laura Jiménez-Álvarez, Luis G. Gu
Medicina.2024; 60(1): 168. CrossRef
TP53R175H mutation promotes breast cancer cell proliferation through CORO1A–P38 MAPK pathway regulation
Yali Su, Jiaxuan Zhao, Haoran Fu, Zeliang Liu, Panyan Du, Jianxia Zheng, Jinghua Wu, Jinghua Zhang
Biochemical Pharmacology.2024; 221: 116047. CrossRef
TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer
Akiko Arimura, Kazuko Sakai, Kazuhisa Kaneshiro, Takafumi Morisaki, Saori Hayashi, Kimihisa Mizoguchi, Mai Yamada, Masaya Kai, Mayumi Ono, Kazuto Nishio, Masafumi Nakamura, Makoto Kubo
Cancers.2024; 16(6): 1184. CrossRef
Exploration of newly synthesized deferasirox derivatives as potential anti-cancer agents via in-vitro and in-silico approaches
Muhammad Zahid Ullah, Zahid Hussain, Syed Ahmad Shakir, Mahnoor Mahmood, Syeda Abida Ejaz, Mubashir Aziz, Ammara Fayyaz, Jamshed Iqbal, Amara Mumtaz
International Journal of Biological Macromolecules.2024; 283: 137971. CrossRef
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
Zhijun Li, Yiqun Han, Jiayu Wang, Binghe Xu
Journal of Personalized Medicine.2023; 13(2): 190. CrossRef
The role of p53 and ki67 in predicting clinical outcome in breast cancer patients
Bhanu Prakash Lalkota, B.J Srinivasa, Mani V. Swamy, Diganta Hazarika, B.M Jeet, K Jyothi, Mithua Ghosh, Suhail M. Sayeed, Mohammad Nasiruddin, Radheshyam Naik
Journal of Cancer Research and Therapeutics.2023; 19(2): 208. CrossRef
Novel microtubule inhibitor SQ overcomes multidrug resistance in MCF-7/ADR cells by inhibiting BCRP function and mediating apoptosis
Xing Chang, Zi Liu, Simeng Cao, Jiang Bian, Dayong Zheng, Nuo Wang, Qi Guan, Yingliang Wu, Weige Zhang, Zengqiang Li, Daiying Zuo
Toxicology and Applied Pharmacology.2022; 436: 115883. CrossRef
Targeted gene next‐generation sequencing reveals genomic profile in a cohort of 46 Chinese patients with breast cancer
Jie Yao, Qian Chen, Jun‐qi Zhu, Rui‐gang Cai
The Journal of Gene Medicine.2022;[Epub] CrossRef
Effect of the elastin-derived peptides (VGVAPG and VVGPGA) on breast (MCF-7) and lung (A549) cancer cell lines in vitro
Konrad A. Szychowski, Bartosz Skóra, Tadeusz Pomianek
Biomedicine & Pharmacotherapy.2022; 151: 113149. CrossRef
p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
Cancer Investigation.2022; 40(10): 879. CrossRef
Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer
Hyo-Jin Kim, Bo-Gyeong Seo, Eun-Chan Seo, Kwang-Min Lee, Cheol Hwangbo
Current Issues in Molecular Biology.2022; 44(12): 5848. CrossRef
An integrative pan-cancer analysis of COPB1 based on data mining
Heyan Chen, Kunlong Li, Yijun Li, Peilin Xie, Jianjun He, Huimin Zhang
Cancer Biomarkers.2021; 30(1): 13. CrossRef
Sex differences in expression of immune elements emerge in children, young adults and mice with osteosarcoma
Lauren J. Mills, Logan G. Spector, David A. Largaespada, Lindsay A. Williams
Biology of Sex Differences.2021;[Epub] CrossRef
GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature
Patrizia Querzoli, Massimo Pedriali, Rosa Rinaldi, Paola Secchiero, Paolo Giorgi Rossi, Elisabetta Kuhn
Diagnostics.2021; 11(4): 604. CrossRef
Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis
Dharambir Kashyap, Vivek Kumar Garg, Elise N. Sandberg, Neelam Goel, Anupam Bishayee
Pharmaceutics.2021; 13(4): 569. CrossRef
Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
Weikai Xiao, Guochun Zhang, Bo Chen, Xiaoqing Chen, Lingzhu Wen, Jianguo Lai, Xuerui Li, Min Li, Hao Liu, Jing Liu, Han Han-Zhang, Analyn Lizaso, Ning Liao
Frontiers in Oncology.2021;[Epub] CrossRef
Syndrome de Peutz–Jeghers et surveillance mammaire : les nouvelles recommandations à propos d’une observation
M. Osada, P. Maniez, N. Taris, C. Mathelin
Gynécologie Obstétrique Fertilité & Sénologie .2021; 49(10): 795. CrossRef
Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
Cancers.2021; 13(14): 3427. CrossRef
Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases
Wachiraphan Supsavhad, Bardes B. Hassan, Jessica K. Simmons, Wessel P. Dirksen, Said M. Elshafae, Nicole A. Kohart, Aylin A. Demirer, Thomas J. Rosol
Veterinary Sciences.2021; 8(8): 153. CrossRef
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines
Ashkan Shahbandi, Hoang D. Nguyen, James G. Jackson
Trends in Cancer.2020; 6(2): 98. CrossRef
The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection
Feng Zeng, Jianfu Heng, Xinwu Guo, Yue Wang, Wenhan Wu, Lili Tang, Min Chen, Shouman Wang, Hongyu Deng, Jun Wang
Breast Cancer Research and Treatment.2020; 180(1): 237. CrossRef
Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
Zongbi Yi, Fei Ma, Guohua Rong, Yanfang Guan, Chunxiao Li, Binghe Xu
Cancer Communications.2020; 40(6): 260. CrossRef
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer
Gu Xiao, Devon Lundine, George K. Annor, Jorge Canar, Viola Ellison, Alla Polotskaia, Patrick L. Donabedian, Thomas Reiner, Galina F. Khramtsova, Olufunmilayo I. Olopade, Alexander Mazo, Jill Bargonetti
Cancer Research.2020; 80(3): 394. CrossRef
Genomic analysis of racial differences in triple negative breast cancer
Chang-Sheng Chang, Eiko Kitamura, Joan Johnson, Roni Bollag, Lesleyann Hawthorn
Genomics.2019; 111(6): 1529. CrossRef
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy
Hyeon Jeong Oh, Jeong Mo Bae, Xianyu Wen, Seorin Jung, Younghoon Kim, Kyung Ju Kim, Nam-Yun Cho, Jung Ho Kim, Sae-Won Han, Tae-You Kim, Gyeong Hoon Kang
British Journal of Cancer.2019; 120(8): 797. CrossRef
Immunostaining for p53 and p16CDKN2A Protein Is Not Predictive of Prognosis for Dogs with Malignant Mammary Gland Neoplasms
John S Munday, Harsha Ariyarathna, Danielle Aberdein, Neroli A Thomson
Veterinary Sciences.2019; 6(1): 34. CrossRef
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
Paul B. Mullan, Victoria Bingham, Paula Haddock, Gareth W. Irwin, Elaine Kay, Stephen McQuaid, Niamh E. Buckley
BMC Cancer.2019;[Epub] CrossRef
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
Jing-ping Li, Xiang-mei Zhang, Zhenzhen Zhang, Li-hua Zheng, Sonali Jindal, Yun-jiang Liu
Medicine.2019; 98(18): e15449. CrossRef
Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad
PLOS ONE.2019; 14(6): e0218030. CrossRef
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
Elisabetta Munzone, Kathryn P. Gray, Caterina Fumagalli, Elena Guerini-Rocco, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Roswitha Kammler, Giuseppe Viale, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Meredith M. Regan, Aron Goldhirsch, Massimo B
Breast Cancer Research and Treatment.2018; 170(2): 351. CrossRef
Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo
Liangjian Xiang, Xiaoyu Xu, Shuo Zhang, Dongyan Cai, Xiaofeng Dai
Free Radical Biology and Medicine.2018; 124: 205. CrossRef
Genetic Markers in Triple-Negative Breast Cancer
Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch
Clinical Breast Cancer.2018; 18(5): e841. CrossRef
Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy‐treated triple negative breast cancer
Soo Youn Bae, Seung Pil Jung, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam
The Kaohsiung Journal of Medical Sciences.2018; 34(12): 663. CrossRef
Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
Yanli Luo, Wentao Huang, Huizhen Zhang, Guang Liu
Oncology Letters.2018;[Epub] CrossRef
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman
PLOS ONE.2017; 12(2): e0172324. CrossRef
Alcohol promotes migration and invasion of triple‐negative breast cancer cells through activation of p38 MAPK and JNK
Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Xiaohe Yang
Molecular Carcinogenesis.2017; 56(3): 849. CrossRef
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
Zongbi Yi, Fei Ma, Chunxiao Li, Rongrong Chen, Lifang Yuan, Xiaoying Sun, Xiuwen Guan, Lixi Li, Binliang Liu, Yanfang Guan, Haili Qian, Binghe Xu
Scientific Reports.2017;[Epub] CrossRef
TP53 gene expression levels and tumor aggressiveness in canine mammary carcinomas
Táya F. Oliveira, Tábata Maués, Mariana S. Ramundo, Agnes Marie S. Figueiredo, Marcela F. V. de Mello, Kênia B. El-Jaick, Maria de Lourdes G. Ferreira, Ana Maria R. Ferreira
Journal of Veterinary Diagnostic Investigation.2017; 29(6): 865. CrossRef
Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer
Jisela Dimas-González, Vilma Maldonado-Lagunas, José Díaz-Chávez, María Eugenia López-Arellano, José Muñoz-Camacho, Marco Antonio Terán-Porcayo, Alfredo Lagunas-Martínez
Oncology Reports.2017; 37(5): 3026. CrossRef
Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing
Xi-Xi Chen, Qian Zhong, Yang Liu, Shu-Mei Yan, Zhang-Hua Chen, Shan-Zhao Jin, Tian-Liang Xia, Ruo-Yan Li, Ai-Jun Zhou, Zhe Su, Yu-Hua Huang, Qi-Tao Huang, Li-Yun Huang, Xing Zhang, Yan-Na Zhao, Jin-Ping Yun, Qiu-Liang Wu, Dong-Xin Lin, Fan Bai, Mu-Sheng Z
Nature Communications.2017;[Epub] CrossRef
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
Ji-Yeon Kim, Eunjin Lee, Kyunghee Park, Woong-Yang Park, Hae Hyun Jung, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Oncotarget.2017; 8(17): 27997. CrossRef
miR-34a expression in human breast cancer is associated with drug resistance
Zhi-Hua Li, Xueling Weng, Qiu-Yun Xiong, Jian-Hong Tu, An Xiao, Wei Qiu, Yu Gong, Er-Wei Hu, Songyin Huang, Ya-Li Cao
Oncotarget.2017; 8(63): 106270. CrossRef
Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer
Min Chong Kim, Jung Eun Choi, Soo Jung Lee, Young Kyung Bae
Annals of Surgical Oncology.2016; 23(11): 3524. CrossRef
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway
Jingwen Xu, Mengting Han, Jiwei Shen, Qi Guan, Zhaoshi Bai, Binyue Lang, Huijuan Zhang, Zengqiang Li, Daiying Zuo, Weige Zhang, Yingliang Wu
Cancer Letters.2016; 383(1): 9. CrossRef

17,094 View
332 Download
50 Web of Science
45 Crossref

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea: Hee Kyung Kim, Jun Soo Ham, Seonggyu Byeon, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Jinhyun Cho, Ji Yun Lee, Sung Hee Lim, Hae Su Kim, Ji-Yeon Kim, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se Kyung Lee, Soo Youn Bae, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2016;48(4):1382-1388. Published online March 11, 2016; DOI: https://doi.org/10.4143/crt.2015.423

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to assess the tumor characteristics and long-term clinical outcomes of adjuvant treatments after surgery with a curative aim for patients with breast cancer who are 65 years and older. Materials and Methods Patients with breast cancer who underwent curative surgery from 2000 to 2009 were analyzed (n=4,388). Tumor characteristics and survival outcome were compared by dividing the patients into two age groups (< 65 and ≥ 65 years old). The Kaplan-Meier method was used for comparison of survival rates by log-rank test, and a Cox regression model was used to examine the effect of variables.
Results
Among 4,388 patients with invasive breast cancer, 317 patients (7.2%) were 65 years or older and the median age of all patients was 47 years (range, 18 to 91 years). Tumor characteristics were similar between the two age groups, but the older patients were treated less often with adjuvant treatments. During a median follow-up period of 122 months, recurrence-free survival (RFS) was equivalent for patients 65 years and older compared to younger patients, but significantly worse in overall survival (OS) and breast cancer–specific survival (BCSS) (5-year OS, 94.3% vs. 90.5%; p < 0.001 and 5-year BCSS, 94.7% vs. 91.8%; p=0.031). In the multivariate model, age ≥ 65 years old was identified as an independent risk factor for OS and RFS. Conclusion Elderly breast cancer appeared to have worse outcomes with very low prevalence in Korea, despite similar tumor characteristics. More active adjuvant therapies would have a role for aggressive subtypes for fit, elderly patients.

Citations

Citations to this article as recorded by

HISTOPATHOLOGICAL AND BIOLOGICAL BEHAVIOR OF BREAST CANCER IN ELDERLY KURDISH WOMEN
Kamal Saeed, Shewaz Salih
JOURNAL OF SULAIMANI MEDICAL COLLEGE.2023; 13(4): 11. CrossRef
Analysis of the tumor characteristics in young age breast cancer patients using collaborative stage data of the Korea Central Cancer Registry
Junyup Kim, Seri Hong, Jae Jun Lee, Young-Joo Won, Eun Sook Lee, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Eun-Gyeong Lee, Heein Jo, Hyun Hee Kim, So-Youn Jung
Breast Cancer Research and Treatment.2021; 187(3): 785. CrossRef
Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study
Kung-Hung Lin, Huan-Ming Hsu, Kuo-Feng Hsu, Chi-Hong Chu, Zhi-Jie Hong, Chun-Yu Fu, Yu-Ching Chou, Golshan Mehra, Ming-Shen Dai, Jyh-Cherng Yu, Guo-Shiou Liao, Jason Chia-Hsun Hsieh
PLOS ONE.2021; 16(12): e0261258. CrossRef
Could lymph node evaluation be eliminated in nearly 50% of women with early stage ER/PR positive breast cancer?
Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L. Tenofsky
The American Journal of Surgery.2020; 220(6): 1417. CrossRef
Overall survival of elderly patients with breast cancer is not related to breast-cancer specific survival: A single institution experience in Japan
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
Breast Disease.2018; 37(4): 177. CrossRef
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
Chiara Mandoj, Laura Pizzuti, Domenico Sergi, Isabella Sperduti, Marco Mazzotta, Luigi Di Lauro, Antonella Amodio, Silvia Carpano, Anna Di Benedetto, Claudio Botti, Francesca Ferranti, Anna Antenucci, Maria Gabriella D’Alessandro, Paolo Marchetti, Silveri
Journal of Translational Medicine.2018;[Epub] CrossRef
Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
Majid Akrami, Afrooz Sepahdar, Peyman Arasteh, Sedigheh Tahmasebi, Vahid Zangouri, Azam Askari, Babak Pezeshki, Abdolrasoul Talei
World Journal of Surgical Oncology.2018;[Epub] CrossRef
Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice
Jessemae L. Welsh, Tanya L. Hoskin, Courtney N. Day, Elizabeth B. Habermann, Matthew P. Goetz, Judy C. Boughey
Annals of Surgical Oncology.2017; 24(10): 2881. CrossRef
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer
Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
Medicine.2016; 95(44): e5302. CrossRef

12,547 View
154 Download
8 Web of Science
9 Crossref

Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer: Haeyoung Kim, Dae-Yeon Cho, Doo Ho Choi, Gee Hue Jung, Inkyung Shin, Won Park, Seung Jae Huh, Seok Jin Nam, Jeong Eon Lee, Won Ho Gil, Seok Won Kim; Cancer Res Treat. 2016;48(3):955-961. Published online January 19, 2016; DOI: https://doi.org/10.4143/crt.2015.191

Abstract PDF PubReader ePub

Purpose
The aim of the current study is to assess the spectrum of genetic variation in the BRIP1 gene among Korean high-risk breast cancer patients who tested negative for the BRCA1/2 mutation.
Materials and Methods
Overall, 235 Korean patientswith BRCA1/2 mutation–negative high-risk breast cancerwere screened for BRIP1 mutations. The entire BRIP1 gene was analyzed using fluorescent-conformation sensitive gel electrophoresis. In silico analysis of BRIP1 variants was performed using PolyPhen-2 and SIFT.
Results
A total of 20 sequence alterations including 12 exonic and eight intronic variantswere found. Among the 12 exonic variants, 10 were missense and two were silent mutations. No protein-truncating mutation was found among the tested patients. Among the 10 missense variants, four (p.L263F, p.L340F, p.L474P, and p.R848H) were predicted to be pathogenic by both PolyPhen-2 and SIFT, and these variants were found in five patients. Of the four missense variants, p.L263F, p.L474P, and p.R848H localize to regions between the helicase motifs, while p.L340F resides in an iron-sulfur domain of BRIP1.
Conclusion
No protein-truncating mutation in BRIP1 was found among the tested patients. The contribution of BRIP1 variants is thought to be minor in Korean non-BRCA1/2 high-risk breast cancer.

Citations

Citations to this article as recorded by

Identification of pathogenic germline variants in a large Chinese lung cancer cohort by clinical sequencing
Zhe Yu, Zirui Zhang, Jun Liu, Xiaoying Wu, Xiaojun Fan, Jiaohui Pang, Hua Bao, Jiani Yin, Xue Wu, Yang Shao, Zhengcheng Liu, Fang Liu
Molecular Oncology.2024; 18(5): 1301. CrossRef
Iron–Sulfur Clusters: Assembly and Biological Roles
Nunziata Maio
Inorganics.2024; 12(8): 216. CrossRef
Evaluation of 17 genetic variants in association with leukemia in the north Indian population using MassARRAY Sequenom
Amrita Bhat, Gh. Rasool Bhat, Sonali Verma, Bhanu Sharma, Divya Bakshi, Deepak Abrol, Supinder Singh, Raies Ahmed Qadri, Ruchi Shah, Rakesh Kumar
Journal of Biochemical and Molecular Toxicology.2021;[Epub] CrossRef
Cancer-associated mutations in the iron-sulfur domain of FANCJ affect G-quadruplex metabolism
Diana C. Odermatt, Wei Ting C. Lee, Sebastian Wild, Stanislaw K. Jozwiakowski, Eli Rothenberg, Kerstin Gari, Andrew Deans
PLOS Genetics.2020; 16(6): e1008740. CrossRef
Helicase-inactivating BRIP1 mutation yields Fanconi anemia with microcephaly and other congenital abnormalities
Lara Kamal, Sarah B. Pierce, Christina Canavati, Amal Abu Rayyan, Tamara Jaraysa, Orit Lobel, Suhair Lolas, Barbara M. Norquist, Grace Rabie, Fouad Zahdeh, Ephrat Levy-Lahad, Mary-Claire King, Moien N. Kanaan
Molecular Case Studies.2020; 6(5): a005652. CrossRef
Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer
Ji Soo Park, Seung-Tae Lee, Eun Ji Nam, Jung Woo Han, Jung-Yun Lee, Jieun Kim, Tae Il Kim, Hyung Seok Park
BMC Cancer.2018;[Epub] CrossRef
Mutation status of RAD51C,PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations
Katsutoshi Sato, Mio Koyasu, Sachio Nomura, Yuri Sato, Mizuho Kita, Yuumi Ashihara, Yasue Adachi, Shinji Ohno, Takuji Iwase, Dai Kitagawa, Eri Nakashima, Reiko Yoshida, Yoshio Miki, Masami Arai
Cancer Science.2017; 108(11): 2287. CrossRef
Mutational analysis of FANCJ helicase
Manhong Guo, Venkatasubramanian Vidhyasagar, Tanu Talwar, Ahmad Kariem, Yuliang Wu
Methods.2016; 108: 118. CrossRef

14,099 View
240 Download
8 Web of Science
8 Crossref

Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer: Ji Yun Lee, Sung Hee Lim, Min-Young Lee, Haesu Kim, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Insuk Sohn, Won Ho Gil, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park; Cancer Res Treat. 2015;47(4):765-773. Published online January 13, 2015; DOI: https://doi.org/10.4143/crt.2014.168

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to evaluate the role of regular postoperative surveillance to improve the prognosis of patients with breast cancer after curative surgery. Materials and Methods We retrospectively analyzed the medical records of 4,119 patients who received curative surgery for breast cancer at Samsung Medical Center between January 2000 and September 2008. Patients were divided into two groups (group I, regular postoperative surveillance; group II, control group) according to their post-therapy follow-up status for the first 5 years after surgery. Results Among the 3,770 patients selected for inclusion, groups I and II contained 3,300 (87%) and 470 (13%) patients, respectively. The recurrence rates at 5 years for groups I and II were 10.6% and 16.4%, respectively (hazard ratio, 0.85; 95% confidence interval [CI], 0.67 to 1.09; p=0.197). The 10-year mortality cumulative rates were 8.8% for group I and 25.4% for group II (hazard ratio, 0.28; 95% CI, 0.22 to 0.35; p < 0.001). In multivariate analysis for recurrence-free survival (RFS), age over 40 years (p < 0.001), histologic grade 1 (p < 0.001), and pathologic stage I (p < 0.001) were associated with longer RFS but not with follow- up status. Multivariate analysis for overall survival (OS) revealed that patients in group I showed significantly improved OS (hazard ratio, 0.29; 95% CI, 0.23 to 0.37; p < 0.001). Additionally, age over 40 years, histologic grade I, and pathologic stage I were independent prognostic factors for OS. Conclusion Regular follow-up for patients with breast cancer after primary surgery resulted in clinically significant improvements in patient OS.

Citations

Citations to this article as recorded by

Follow-up strategy and survival for five common cancers: A meta-analysis
Boris Galjart, Diederik J. Höppener, Joachim G.J.V. Aerts, Christiaan H. Bangma, Cornelis Verhoef, Dirk J. Grünhagen
European Journal of Cancer.2022; 174: 185. CrossRef
Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry
Ji-Yeon Kim, Danbee Kang, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong Han Yu, Se Kyung Lee, Young-Hyuck Im, Jin Seok Ahn, Eliseo Guallar, Juhee Cho, Yeon Hee Park
Journal of Global Oncology.2019; (5): 1. CrossRef
Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
Angela Lamarca, Hamish Clouston, Jorge Barriuso, Mairéad G McNamara, Melissa Frizziero, Was Mansoor, Richard A Hubner, Prakash Manoharan, Sarah O’Dwyer, Juan W Valle
Journal of Clinical Medicine.2019; 8(10): 1630. CrossRef
Analysis of patient-detected breast cancer recurrence
Trishul Kapoor, Sean Wrenn, Peter Callas, Ted A. James
Breast Disease.2017; 37(2): 77. CrossRef

11,955 View
89 Download
3 Web of Science
4 Crossref

Primary Follicular Lymphoma in a Male Breast: A Case Report: Seung Pil Jung, Kang Min Han, Seok Jin Kim, Seok Jin Nam, Jeoung Won Bae, Jeong Eon Lee; Cancer Res Treat. 2014;46(1):104-107. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.104

Abstract PDF PubReader ePub

Primary breast lymphoma (PBL) is a rare disease, particularly in males. Diffuse large B cell lymphoma is the most common PBL, while follicular lymphoma is less common. Furthermore, primary follicular lymphoma of a male breast is rarely reported. We report a male patient with primary follicular lymphoma of the breast and hepatocellular carcinoma (HCC). A 46-year-old man was diagnosed with liver cirrhosis secondary to chronic hepatitis B infection. Ten years later, he underwent segmentectomy of the liver due to HCC. Another 5 months later, he presented with a painless mass in the right chest wall. The mass was diagnosed as follicular lymphoma of the breast. The stage was IEA and he did not receive adjuvant therapy. Although only a few cases have been reported, lymphoma should be considered as a possible cause of breast mass, even in male patients.

Citations

Citations to this article as recorded by

Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review
Fengbo Huang, Yachao Ruan, Xiaojuan He, Hui Lian, Jinhua Yang
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Primary breast lymphoma in males: Incidence, demographics, prognostic factors, survival, and comparisons with females
Jie Zhang, Binbin Ma, Hong Ji, Rong Guo
Frontiers in Surgery.2022;[Epub] CrossRef
Hematologic Malignancies of the Breast: A Contemporary Series Investigating Incidence, Presentation, Accuracy of Diagnosis on Core Needle Biopsy, and Hormone Receptor Expression
Marie-Christine Guilbert, Jason L Hornick, Sona A Chikarmane, Susan C Lester
Breast Cancer: Basic and Clinical Research.2019;[Epub] CrossRef

15,431 View
65 Download
5 Web of Science
3 Crossref

Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer: Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im; Cancer Res Treat. 2011;43(2):89-95. Published online June 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.2.89

Abstract PDF PubReader ePub

PURPOSE
The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.
MATERIALS AND METHODS
Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.
RESULTS
The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).
CONCLUSION
Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'

Citations

Citations to this article as recorded by

Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis
Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad
Biomedicines.2024; 12(5): 1075. CrossRef
Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways
Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang
Phytotherapy Research.2024; 38(6): 2860. CrossRef
Acro metastasis: A rare presentation in a common cancer
Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour
Current Problems in Cancer: Case Reports.2024; 14: 100292. CrossRef
Concise review: breast cancer stems cells and their role in metastases
Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard
Annals of Medicine & Surgery.2024;[Epub] CrossRef
Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras
Current Oncology.2023; 30(2): 1416. CrossRef
Surgery in the Setting of Metastatic Breast Cancer
Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup
Current Breast Cancer Reports.2023; 15(1): 37. CrossRef
Team Approach: Management of Pathologic Fractures
Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach
JBJS Reviews.2023;[Epub] CrossRef
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan
European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477. CrossRef
Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk
BMC Cancer.2023;[Epub] CrossRef
SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches
Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu
Cell Research.2023; 33(6): 464. CrossRef
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill
International Journal of Molecular Sciences.2023; 24(10): 8488. CrossRef
Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer
Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun
BMC Cancer.2023;[Epub] CrossRef
Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept
Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo
Journal of Clinical Medicine.2022; 11(13): 3589. CrossRef
Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis
Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran
BioMed Research International.2022; 2022: 1. CrossRef
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis
Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong
International Journal of Pharmaceutics.2022; 625: 122092. CrossRef
Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq
Cancer Management and Research.2022; Volume 14: 2519. CrossRef
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng
Cancers.2022; 14(23): 5727. CrossRef
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?
E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse
Critical Reviews in Oncology/Hematology.2021; 157: 103146. CrossRef
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
European Journal of Cancer.2021; 144: 341. CrossRef
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone
Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang
Translational Oncology.2021; 14(2): 100993. CrossRef
Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis
Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim
Bone.2021; 144: 115775. CrossRef
Diagnosis and referral of adults with suspected bony metastases
Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson
BMJ.2021; : n98. CrossRef
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos
Cancers.2021; 13(6): 1458. CrossRef
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue
European Journal of Radiology.2021; 141: 109821. CrossRef
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser
The Breast.2021; 58: 173. CrossRef
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
Nature Communications.2021;[Epub] CrossRef
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak
Clinical Breast Cancer.2020; 20(1): e54. CrossRef
Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice
Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas
Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113. CrossRef
MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9
Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu
Bone.2020; 130: 115139. CrossRef
Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke
Clinical Breast Cancer.2020; 20(3): 209. CrossRef
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti
PLOS ONE.2020; 15(4): e0227256. CrossRef
International Framework for Red Flags for Potential Serious Spinal Pathologies
Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe
Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350. CrossRef
Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu
The Oncologist.2020; 25(8): e1170. CrossRef
Imaging diagnosis of metastatic breast cancer
Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh
Insights into Imaging.2020;[Epub] CrossRef
Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells
Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo
Breast Cancer Research and Treatment.2020; 184(1): 23. CrossRef
Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons
Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli
Frontiers in Bioengineering and Biotechnology.2020;[Epub] CrossRef
The influence of breast cancer subtype on survival after palliative radiation for osseous metastases
Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins
Cancer Medicine.2020; 9(23): 8979. CrossRef
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao
Breast Cancer Research and Treatment.2019; 173(1): 225. CrossRef
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study
Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li
European Journal of Surgical Oncology.2019; 45(8): 1364. CrossRef
The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis
Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage
Nature Communications.2019;[Epub] CrossRef
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova
Clinical Breast Cancer.2018; 18(1): e41. CrossRef
Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan
Breast Cancer Research and Treatment.2018; 167(2): 579. CrossRef
Breast cancer bone metastases: pathogenesis and therapeutic targets
Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan
The International Journal of Biochemistry & Cell Biology.2018; 96: 63. CrossRef
Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data
Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu
Journal of Bone Oncology.2018; 11: 38. CrossRef
Breast osteoblast-like cells: a new biomarker for the management of breast cancer
Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno
British Journal of Cancer.2018; 119(9): 1129. CrossRef
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
Breast Cancer.2017; 24(3): 473. CrossRef
Pattern of metastatic spread and subcategories of breast cancer
Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner
Archives of Gynecology and Obstetrics.2017; 295(1): 211. CrossRef
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid
Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini
The Breast Journal.2017; 23(5): 610. CrossRef
The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu
The Journal of Pathology.2017; 242(1): 73. CrossRef
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
I Bado, Z Gugala, S A W Fuqua, X H-F Zhang
Oncogene.2017; 36(32): 4527. CrossRef
Which red flags aid the early detection of metastatic bone disease in back pain?
Laura Finucane, Susan Greenhalgh, James Selfe
Physiotherapy Practice and Research.2017; 38(2): 73. CrossRef
Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An
Medicine.2017; 96(50): e8985. CrossRef
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Shinji Ohno
Clinical Breast Cancer.2016; 16(4): 238. CrossRef
Quality of life and symptom burden in patients with metastatic breast cancer
Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma
Supportive Care in Cancer.2016; 24(9): 4035. CrossRef
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann
BMC Cancer.2016;[Epub] CrossRef
Prolactin receptor in breast cancer: marker for metastatic risk
Carrie S Shemanko
Journal of Molecular Endocrinology.2016; 57(4): R153. CrossRef
Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers
Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno
Clinical Breast Cancer.2015; 15(1): 37. CrossRef
Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer
Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney
Clinical Breast Cancer.2015; 15(2): 117. CrossRef
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
D.K. Woolf, A.R. Padhani, A. Makris
Annals of Oncology.2015; 26(6): 1048. CrossRef
Survival time according to the year of recurrence and subtype in recurrent breast cancer
Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura
The Breast.2015; 24(5): 588. CrossRef
Cases of Bone-only Metastasis in Recurrent Breast Cancer
Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484. CrossRef
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh
Journal of Breast Cancer.2013; 16(1): 66. CrossRef
Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons
Journal of Bone Oncology.2013; 2(4): 137. CrossRef
Zooming in on the schedule of bone-modifying drugs
Miguel Martin, Sara López-Tarruella
The Lancet Oncology.2013; 14(7): 575. CrossRef
Bone metastases: assessment, management and treatment options
Carole Farrell
British Journal of Nursing.2013; 22(Sup7): S4. CrossRef
Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien
K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah
Médecine Nucléaire.2012; 36(10): 574. CrossRef

14,614 View
143 Download
67 Crossref

Preliminary Results of Postoperative Radiotherapy after Breast Conserving Surgery in Early Breast Cancer: Seung Hee Chang, Seung Jae Huh, Jung Hyun Yang, Do Hoon Lim, Seok Jin Nam, Sung Soo Yoon, Yong Chan Ahn, Dae Yong Kim, Suk Won Park, Moon Kyung Kim; J Korean Cancer Assoc. 2000;32(4):775-782.

Abstract PDF: PURPOSE
To evaluate treatment results of breast conserving surgery and radiation therapy including survival rates, patterns of failure, and complication and to analyze prognostic factors.
MATERIALS AND METHODS
Retrospective analysis was carried out for 111 (112 cases) consecutive patients with breast cancer treated by radiation therapy after breast conserving surgery from October 1994 to April 1997. The median follow up was 45 months (range 10~66). AJCC staging was as follows: 16 cases (14%) for ductal carcinoma in situ, 46 cases (41%) for stage I, 33 cases (30%) for stage IIa, and 17 cases (15%) for stage IIb. Radiation therapy after breast conserving surgery was delivered to whole breast with 50.4 Gy and additional 10 Gy electron beam boost to tumor bed. Adjuvant CMF or CAF chemotherapy was performed in 61 patients.
RESULTS
Overall three- and five-year survivals were 99% and 95%, and progression-free survival were 93%, 87%, respectively. Treatment failure occurred in 11 cases (10%); loco-regional recur rence in six; distant metastasis in five. Univariate analysis showed prognostic factor affecting survival was only T-stage. Acute radiation dermatitis were found in five cases (4%), and chronic complications were found in five (4%); one case with amputation of nipple, two cases with lymphedema requiring rehabilitation therapy and two cases with symptomatic radiation pneu monitis requiring steroid therapy.
CONCLUSION
Breast conserving therapy of early breast cancer including ductal carcinoma in situ showed high survival rates and low complications, and T stage was prognostic factor for survival. But further follow-up should be needed.

3,060 View
15 Download

Insular Carcinoma: An Aggressive Subtype of Differentiated Thyroid Neoplasms: Seok Jin Nam, Sang Dal Lee, Young Ryun Oh, Jung Hyun Yang; J Korean Cancer Assoc. 2000;32(1):229-234.

Abstract: PURPOSE
Insular carcinoma is a rare subtype of thyroid cancer which is first described by Carcangiu in 1984. It is intermediate in aggressiveness between well differentiated and anaplastic thyroid carcinoma. But its origin, clinical features and prognosis are not yet clearly understood. We wanted to evaluate the clinical features, histologic characteristics and the prognosis of the insular thyroid carcinoma.
MATERIALS AND METHODS
We studied 4 cases of insular thyroid carcinoma treated in Samsung Medical Center from March 1996 to April 1998. Age, sex, clinical features, treatment, pathology and follow up findings were reviewed, retrospectively.
RESULTS
All patients were female and mean age was 44 years. Three of four patients complained anterior neck mass and one patient complained low back pain and paresthesia of right thigh. Two patients had metastatic bone lesions at the time of diagnosis. Preoperative fine needle aspiration cytology could diagnose follicular neoplasm in 2 cases and papillary carcinoma in 1. We performed total or completion thyroidectomy and radioactive iodine therapy in 3 cases and radioactive iodine therapy alone in one. Extra- thyroidal invasion, vascular invasion and multicentricity was noted in two cases. All four patients showed recurrence or distant metastasis in follow up period of 10~31 months and 2 of them died of distant metastasis.
CONCLUSION
Insular carcinoma is a special type of thyroid carcinoma with aggressive clinical course. Recurrence and extrathyroidal involvements are common and the prognosis is poorer than other well differentiated thyroid carcinoma.

3,417 View
13 Download

Correlation between VEGF Expression and Prognostic Factors in Breast Cancer: Jung Eun Jang, Sang Yun Choi, Chan Hyung Park, Young Hyeh Ko, Ki Hyun Kim, Hyun Sik Jeong, Kwang Sung Ahn, Jung Hyun Yang, Seok Jin Nam, Sung Soo Yoon; J Korean Cancer Assoc. 1999;31(3):483-491.

Abstract PDF: PURPOSE
Archival tissues of breast cancer patients were examined for VEGF expression to evaluate the relationship with other clinicopathologic factors and prognostic significance of VEGF in breast cancer.
MATERIALS AND METHODS
Paraffin sections from 76 patients with invasive breast cancer who have been treated at Samsung Medical Center from December, 1994 to April, 1998 were examined for VEGF expression by immunohistochemical staining using anti-VEGF antibody. We analyzed relationships between VEGF expression and tumor size, tumor stage, metastasis, steroid honnone receptors, p53, disease recurrence and survival.
RESULTS
Immunostaining showed variable VEGF positivity in the malignant cells and VEGF was detected more frequently in tumors than in adjacent non-tumorous breast tissues. 74 out of 76 (97.4%) was positive for VEGF. We found that the expression of VEGF was strongly correlated with the stages of breast tumor (P=0.020), lymph node metastasis (P=0.043) and PR (P=0.016). However, we could not find statistically significant relationship between VEGF expression and tumor size, ER, p53 and distant metastasis.
CONCLUSION
VEGF may be a useful prognostic indicator in patients with breast cancer, especially correlated with tumor stage and lymph node metastasis. This result warrants further study to confirm our findings.

3,622 View
31 Download

Effectiveness of Sentinel Node Biopsy in the Prediction of Axillary Nodal Status in 111 Patients with Breast Cancer: Jeong Hyun Yang, Hae Kyung Lee, Seok Jin Nam; J Korean Cancer Assoc. 1998;30(5):951-955.

Abstract PDF: PURPOSE
Recently, results of many trials that intend to decide the axillary status through more conservative procedures are reported. One of these is sentinel node biopsy. This method is regarded as reasonable and selective. Some investigators tend to omit axillary dissection in the patient who is determined to have negative node clinically and negative result in sentinel node biopsy procedure. This study was designed to know how accurate the sentinel node biopsy method can predict axillary nodal status.
MATERIALS AND METHOD
The patients group was selected from Department of Surgery at SMC, consisting of 111 patients with surgically curable breast cancer from Sept. 1995 to Apr. 1997. Isosulfan blue was injected in the center of mass and the margins of 4 quadrant under the general anesthesia. Axillary dissection was done 5 minutes after injection to identify the stained lymphatics. When stained lymphatics were identified, dissection was performed along the lymphatics bidirectionally to detect the stained lymph node nearest to the primary tumor (sentinel node). After frozen biopsy of sentinel node, routine axillary node dissection was performed. Results of frozen biopsy were compared with the final pathologic results.
RESULTS
Sentinel node was detected in 80 of the 111 cases (72.1%) and there were 44 (55.0%) axillary metastasis cases in sentinel node detection group. In 14 of 44 cases, sentinel node was only positive. In 5 of 41, sentinel node were falsely negative for malignancy. Negative predictive value of the method is 87.8% (36/41).
CONCLUSION
Sentinel node biopsy method can predict the axillary nodal status in patients with breast cancer. This method can lead to more conservative treatment, eventually omitting axillary nodal dissection in selected patients.

2,577 View
12 Download

Primary Leiomyosarcoma of the Breast: Jeong Hyun Yang, Hae Kyung Lee, Seok Jin Nam, Gyu Rae Kim; J Korean Cancer Assoc. 1998;30(2):421-424.

Abstract PDF: We describe a 42-year-old woman with a primary leiomyosarcoma of the breast. It is an extremely rare tumor, with only about 16 cases reported. Usually it is presented with palpable mass of benign characters. The origin of the tumor is controversal and the differential diagnosis includes other sarcomas and metastatic ones. The uncertain behavior of it makes the management difficult but conservative surgery is available in the case of anatomically suitable. Axillary lymphatic dissection is not needed and the roles of the chemotherapy and radiotherapy are not clear. Some studies revealed a local invasion and degree of cellular atypia as some prognostic predictive value.

2,394 View
19 Download

Efficiency of Positron Emission Tomography (PET) in Diagnosis of Breast Cancer: Seok Jin Nam, Jee Hyung Noh, Byung Tae Kim; J Korean Cancer Assoc. 1997;29(2):235-242.

Abstract PDF: PURPOSE
PET developed on the basis of biochemical characteristics of malignant tissues where the increase in glucose metabolism. Therefore, early and accurate detection of primary or metastatic lesion can be expected. This study is to compare PET and other traditional methods in detection of primary breast carcinoma and metastatic lesion, and to find the advantage of PET.
MATERIALS AND METHODS
We compared and analysed the results of PET, US, mammogr aphy, bone scan, CT and biopsy reports of the 46 patients who were examined in our hospital from September 1, 19094 to July 31, 1995. PET Trace 200 cyclotron and PET Advanced Scenner were used for FDG synthesis and imaging respectively.
RESULTS
10 of the 12 cases who had preoperative PET were consistent with the results of mammography and ultrasound and 9 of the 10 cases were consistent with the pathologic results. In one case, which did mammography and PET after excis ional biopsy, PET gaves a false positive result. In the detection of axilliary node metastasis, PeT after excisional biopsy, PET gaves a false positive result. In the detection of axilliary node metastasis, PET shows 100% sensitivity and specificity but bone scan shows 100%, 72.2% respectively.
CONCLUSION
PET is useful for diagnosis of primary breast cancer and is superior to bone scan in specificity for diagnosis of bone metastasis and in early detection of response to treatment. Because PET cannot exclude false (+) in inflamm atory lesion, continuous investigation is needed for establishment of indication and reduction of false (+), false (-).In spite of high cost, PET may become a new and useful diagnostic tool.

2,503 View
16 Download

Endoxifen Concentration Is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients: Beomki Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung-Joo Chae, Se Kyung Lee, Jai Min Ryu, Jeong Eon Lee, Soo-Youn Lee; Received December 5, 2023 Accepted June 16, 2024 Published online June 18, 2024; DOI: https://doi.org/10.4143/crt.2023.1285 [Epub ahead of print]

Abstract PDF PubReader ePub: Purpose
The metabolism of tamoxifen is influenced by various cytochrome p450 enzymes, including CYP2D6 and CYP2C19, leading to variations in the levels of endoxifen, even with the same tamoxifen dose. However, the clinical significance of endoxifen for the prognosis of breast cancer patients remains controversial. This study aimed to elucidate the relevance of endoxifen level to recurrence-free survival censored with tamoxifen discontinuation (RFSt), representing the RFS for tamoxifen itself, of breast cancer patients and determine a suitable cutoff for prognostication.
Materials and Methods
The study included 478 breast cancer patients. Tamoxifen and its metabolites, including endoxifen, were measured using liquid chromatography-tandem mass spectrometry. An optimal cutoff was determined with maximally selected rank statistics. Survival analysis and Cox regression were conducted based on this cutoff.
Results
An endoxifen level of 21.00 ng/mL was the optimal cutoff for prognostication. Survival analysis revealed a statistically significant difference in RFSt between the low endoxifen group (≤ 21.00 ng/mL) and the high endoxifen group (> 21.00 ng/mL) (log-rank test, p=0.032). The 10-year probability of RFSt was 83.2% (95% confidence interval [CI], 77.0 to 89.9) and 88.3% (95% CI, 83.3 to 93.5) in the low and high endoxifen groups, respectively. Multivariable Cox proportional hazards regression indicated endoxifen concentration as a significant factor associated with prognosis.
Conclusion
Endoxifen could serve as a marker for appropriate tamoxifen treatment with a cutoff of 21.00 ng/mL. Based on this cutoff, therapeutic drug monitoring would benefit patients displaying suboptimal endoxifen concentrations.

762 View
68 Download

Author index